Drugs / RP-001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07504263 | Apr 2026 → Dec 2027 expected | colorectal cancer, malignant pancreatic neoplasm | Recurv Pharma Inc | Not yet recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RP-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07504263 ↗ |